10-Q: Dalrada Financial Corporation Reports Q2 2024 Results with Increased Revenue but Continued Losses

Dalrada Financial Corporation's Q2 2024 results show a rise in revenue compared to the same period last year, but the company continues to experience net losses.

Summary

• Dalrada Financial Corporation reported a net loss of $5.44 million for the three months ended December 31, 2023, and a net loss of $10.28 million for the six months ended December 31, 2023.
• Total revenue for the three months ended December 31, 2023, was $6.08 million, compared to $5.25 million for the same period in 2022.
• Total revenue for the six months ended December 31, 2023, was $11.10 million, compared to $9.51 million for the same period in 2022.
• The company's operating expenses were $6.23 million for the three months ended December 31, 2023, and $12.27 million for the six months ended December 31, 2023.
• The company's cash and cash equivalents were $598,438 as of December 31, 2023, down from $812,806 as of June 30, 2023.
• The company has a working capital deficit of $2.68 million as of December 31, 2023.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document indicates a concerning financial situation with significant losses, a working capital deficit, and doubts about the company's ability to continue as a going concern. While there are some positive aspects like revenue growth in certain divisions, the overall sentiment is negative due to the financial instability and operational challenges.

Positives

• Total revenue increased for both the three and six month periods ended December 31, 2023.
• The Genefic division experienced a substantial revenue increase of 118.3% for the three months ended December 31, 2023.
• Operating expenses for Dalrada Precision Manufacturing decreased by 57% for the three months ended December 31, 2023.
• Operating expenses for Dalrada Technologies decreased by 16% for the three months ended December 31, 2023.

Negatives

• The company reported a net loss of $5.44 million for the three months ended December 31, 2023, and $10.28 million for the six months ended December 31, 2023.
• Dalrada Climate Technology's revenue decreased by 53.2% for the three months ended December 31, 2023.
• Dalrada Precision Manufacturing's revenue decreased by 42.8% for the three months ended December 31, 2023.
• Dalrada Technologies' revenue decreased by 38.8% for the three months ended December 31, 2023.
• The company's cash and cash equivalents decreased to $598,438 as of December 31, 2023.
• The company has a working capital deficit of $2.68 million as of December 31, 2023.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.
• The company is incurring increased costs as a result of being a publicly traded company.
• The company has a working capital deficit and may need to raise additional capital.
• The company is involved in ongoing legal proceedings.
• The company's internal controls over financial reporting were deemed not effective.

Future Outlook

The company anticipates needing additional liquidity to fund operations and expansion, and plans to support operations by raising capital and accelerating sales and marketing efforts.

Management Comments

• Management is planning to support operations by raising capital, and by accelerating sales & marketing efforts of high-margin heating & cooling units, precision parts, Dalrada Energy Services, DepTecs deposition systems and COVID-19 testing.
• The continuation of the Company as a going concern is dependent upon the continued financial support from its management, its ability to obtain the necessary debt or equity financing and generate profitable operations from the Companys planned future operations.

Industry Context

The company operates in various sectors including healthcare, climate technology, manufacturing, and technology, and is facing challenges common to companies in these sectors, such as competition, regulatory hurdles, and the need for continuous innovation.

Comparison to Industry Standards

• The company's revenue growth in the Genefic division is a positive sign, but the overall losses and working capital deficit are concerning when compared to industry benchmarks.
• The decrease in revenue in the Dalrada Climate Technology division is a negative trend compared to other companies in the renewable energy sector.
• The company's reliance on related party loans is not a standard practice and may raise concerns about financial stability.
• The company's internal control weaknesses are a significant concern compared to industry standards for public companies.

Legal Proceedings

• Dalrada Health Products is involved in a legal dispute with Vivera Pharmaceuticals, Inc. regarding misappropriation of funds.
• Likido Ltd. concluded a dispute with MAPtech PACKAGING LIMITED, resulting in a payment of $429,987 in damages, $42,374 in legal costs, and 19,754 as reimbursement for arbitration fees and expenses.

Related Party Transactions

• The company received cash funding or expenses paid on behalf of the company from related parties totaling $1,034,600 and $1,854,380 for the three and six months ended December 31, 2023, respectively.
• The company has significant related party notes payable, with a total of $4,834,971 outstanding as of December 31, 2023.
• The company leases a commercial building in Escondido, California from a related party.
• The company acquired Dalrada Technology Ltd. from related parties to the Chairman and CEO of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity sales.
• Employees may be affected by the company's financial instability.
• Customers may be concerned about the company's ability to fulfill contracts and provide ongoing services.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to raise capital to fund operations and expansion.
• The company plans to accelerate sales and marketing efforts of high-margin products and services.
• The company needs to address the identified weaknesses in internal controls over financial reporting.

Key Dates

Keywords

financial results, revenue, net loss, operating expenses, stock-based compensation, working capital, going concern, legal proceedings, healthcare, climate technology, manufacturing, technology